REVIEW article
Front. Nucl. Med.
Sec. Radiopharmacy and Radiochemistry
Volume 5 - 2025 | doi: 10.3389/fnume.2025.1656374
This article is part of the Research TopicThe Shining Era of Radiometals in Nuclear Medicine: Advancement from Bench to BedsideView all 3 articles
Platinum Group Metals for Nuclear Medicine, a Luxurious Dream or the Future of Imaging and Therapy: A Review
Provisionally accepted
- The University of Tennessee, Knoxville, Knoxville, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Platinum group metals (PGMs) consist of six transition metals: platinum (Pt), palladium (Pd), rhodium (Rh), osmium (Os), iridium (Ir), and ruthenium (Ru). PGMs have been used notably in industrial, electronic, and medical applications. For example, Ir-192 is often utilized in industry to detect structural defects in metal and assess pipeline integrity. Pd-104 is irradiated to produce Pd-103 seeds, used for prostate cancer treatment. Other isotopes of elements in this group can be sourced to facilitate critical applications, discussed in this review. Due to their unique chemical and nuclear properties, these metals may be promising candidates for various nuclear medicine applications, including diagnostic imaging via Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Targeted Radionuclide Therapy (TRT). This review will explore PGMs in nuclear medicine, focusing on their production routes, nuclear characteristics, and suitability for past and future development of radiopharmaceuticals. We will highlight methods for radiochemical separation and purification of each radionuclide, discussing potential challenges and emphasizing the need for further research to ensure sustainability. As the demand for advanced nuclear medicine techniques continues to grow, PGMs may play a significant role in addressing current challenges in the field. We will discuss several radionuclides of interest to
Keywords: Platinum group metals, Platinum, Palladium, Rhodium, Osmium, Iridium, Ruthenium, Nuclear Medicine
Received: 30 Jun 2025; Accepted: 26 Aug 2025.
Copyright: © 2025 Racz and Chaple. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ivis Chaple, The University of Tennessee, Knoxville, Knoxville, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.